Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.

标题
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 34, Issue 4_suppl, Pages TPS465-TPS465
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2017-02-24
DOI
10.1200/jco.2016.34.4_suppl.tps465

向作者/读者发起求助以获取更多资源

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started